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Bauer ketones 23 and 24 from Echinacea paradoxa var. paradoxa inhibit
lipopolysaccharide-induced nitric oxide, prostaglandin E2 and cytokines in
RAW264.7 mouse macrophages
Abstract
Among the nine Echinacea species, E. purpurea, E. angustifolia and E. pallida, have been widely used to treat the
common cold, flu and other infections. In this study, ethanol extracts of these three Echinaceaspecies and E.
paradoxa, including its typical variety, E. paradoxa var. paradoxa, were screened in lipopolysaccharide (LPS)-
stimulated macrophage cells to assess potential anti-inflammatory activity. E. paradoxa var. paradoxa, rich in
polyenes/polyacetylenes, was an especially efficient inhibitor of LPS-induced production of nitric oxide
(NO), prostaglandin E2 (PGE2), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6) by 46%, 32%, 53% and
26%, respectively, when tested at 20 μg/ml in comparison to DMSO control. By bioactivity-guided
fractionation, pentadeca-8Z-ene-11, 13-diyn-2-one (Bauer ketone 23) and pentadeca-8Z, 13Z-
dien-11-yn-2-one (Bauer ketone 24) from E. paradoxa var. paradoxa were found primarily responsible for
inhibitory effects on NO and PGE2 production. Moreover, Bauer ketone 24 was the major contributor to
inhibition of inflammatory cytokine production in LPS-induced mouse macrophage cells. These results
provide a rationale for exploring the medicinal effects of the Bauer ketone-rich taxon, E. paradoxa
var.paradoxa, and confirm the anti-inflammatory properties of Bauer ketones 23 and 24.
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a b s t r a c t
Among the nine Echinacea species, E. purpurea, E. angustifolia and E. pallida, have been widely used to treat
the common cold, ﬂu and other infections. In this study, ethanol extracts of these three Echinacea species
and E. paradoxa, including its typical variety, E. paradoxa var. paradoxa, were screened in lipopolysaccharide
(LPS)-stimulatedmacrophage cells to assess potential anti-inﬂammatory activity.E. paradoxa var.paradoxa,
rich in polyenes/polyacetylenes, was an especially efﬁcient inhibitor of LPS-induced production of nitric
oxide (NO), prostaglandin E2 (PGE2), interleukin-1 beta (IL-1b) and interleukin-6 (IL-6) by 46%, 32%, 53%
and 26%, respectively, when tested at 20 lg/ml in comparison to DMSO control. By bioactivity-guided frac-
tionation, pentadeca-8Z-ene-11, 13-diyn-2-one (Bauer ketone 23) and pentadeca-8Z, 13Z-dien-11-yn-
2-one (Bauer ketone 24) from E. paradoxa var. paradoxa were found primarily responsible for inhibitory
effects on NO and PGE2 production. Moreover, Bauer ketone 24 was the major contributor to inhibition
of inﬂammatory cytokine production in LPS-induced mouse macrophage cells. These results provide a
rationale for exploring the medicinal effects of the Bauer ketone-rich taxon, E. paradoxa var. paradoxa,
and conﬁrm the anti-inﬂammatory properties of Bauer ketones 23 and 24.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Echinacea preparations are among the most widely used dietary
supplements and their annual sales gross $120 million in the US
(2009). There are two main taxonomic systems for Echinacea:
McGregor’s taxonomy (nine species and four varieties, used herein)
(McGregor, 1968) and a more recent morphometric analysis-based
classiﬁcation (four species and eight varieties) (Binns et al., 2002b).
Three species, Echinacea angustifolia, Echinacea purpurea and Echin-
acea pallida, are commonly used for the prevention and treatment
of upper respiratory tract infections, such as the common cold and
inﬂuenza, in North America and Europe.
The efﬁcacy of Echinacea for the treatment of the common cold,
such as shortening duration and alleviating symptoms, has been
observed in some clinical trials, but no clear evidence has demon-
strated prevention of colds (Linde et al., 2006). However, the heter-
ogeneity of clinical studies, in experimental design, Echinacea
preparations used, and outcomes measured, has led to conﬂicting
results (Linde et al., 2006). Moreover, the lack of information
regarding the chemical composition of Echinacea preparations in
many past published studies has made their outcomes difﬁcult to
interpret and compare.
There is a largebody of evidence, based on cell culture andanimal
studies, demonstrating that Echinacea extracts possess immuno-
modulatory, anti-inﬂammatory, antiviral, antioxidant and antimi-
crobial properties (Barnes et al., 2005). It has been reported that
polysaccharides, cichoric acid and alkamides might contribute to
immunological activity via enhancing cytokine production and
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phagocytic activity of macrophages (Goel et al., 2002; Stimpel et al.,
1984). The antiviral effects of Echinacea have been attributed to gly-
coproteins and cichoric acid (Barnes et al., 2005; Bodinet and Bue-
scher, 1991). Anti-inﬂammatory activity has been observed with a
polysaccharide fraction and with polyunsaturated alkamides from
E. angustifolia roots, and echinacoside, alkamides and polyenes/
polyacetylenes from E. pallida (LaLone et al., 2007, 2009; Tubaro
et al., 1987). In addition, polyenes and polyacetylenes from E. pallida
roots have also been reported to induce apoptosis of tumor cells
(Chicca et al., 2008).
In this research, the anti-inﬂammatory activity of Echinacea
species was investigated by using LPS-stimulated RAW264.7
mouse macrophage cells as the research model. PGE2, NO and
inﬂammatory cytokines, secreted by RAW264.7 macrophages un-
der stimulation with LPS, are critical endpoints to evaluate the acti-
vation of macrophages and the magnitude of inﬂammatory
responses. Two goals were addressed: (1) to compare the effective-
ness of ethanol extracts from the roots of various Echinacea species
on the production of PGE2, NO and inﬂammatory cytokines from
LPS-stimulated RAW264.7 macrophages; and (2) to identify the
constituents responsible for any observed bioactivity of these
Echinacea ethanol extracts, and assess the effects of identiﬁed com-
pounds on expression of cyclooxygenase-2 (COX-2) and inducible
nitric oxide synthase (iNOS), the key enzymes to regulate produc-
tion of PGE2 and NO, respectively. All compounds mentioned
throughout the text were numbered and shown in Fig. 1.
2. Results and discussion
2.1. Inhibition of NO, PGE2 and inﬂammatory cytokines production by
Echinacea species/accessions
To assess the anti-inﬂammatory effects of selected Echinacea
species and accessions, six accessions from four Echinacea species
(Table 1) were screened for their ability to inhibit LPS-induced
inﬂammatory response in RAW264.7 macrophages. For all end-
points (NO, PGE2, IL-6, IL-1b and TNF-a), the extracts were tested
at a normalized concentration of 20 lg/ml to compare anti-inﬂam-
matory activity. All the treatments with Echinacea extracts were
compared to the DMSO vehicle control treatment with or without
LPS induction in RAW264.7 cells. Cytotoxicity screening showed no
cytotoxicity with any of these extracts at the screened concentra-
tions (data not shown).
As shown in Table 2, all six Echinacea ethanol extracts signiﬁ-
cantly reduced NO production in LPS-stimulated RAW264.7 cells.
Two accessions of E. paradoxa showed the highest inhibitory activ-
ity with reduction of LPS-induced NO levels by 39% and 46% when
compared to their corresponding controls. LPS-induced PGE2 levels
were signiﬁcantly inhibited by ethanol extracts from E. purpurea,
E. pallida Ames 28968, and E. paradoxa var. paradoxa. LPS-induced
IL-1b and IL-6 levels were inhibited by E. paradoxa var. paradoxa
ethanol extract most potently and by E. pallida PI 631274 to a les-
ser extent. A slight decline in TNF-a production was observed in
LPS-induced RAW264.7 cells treated with E. purpurea, E. paradoxa
and both accessions of E. pallida. In the absence of LPS, all Echinacea
ethanol extract treatments of RAW264.7 cells stimulated TNF-a
level, but levels of IL-1b and IL-6 production were undetectable
(data not shown). It has also been observed that Echinacea purpurea
ethanol extract stimulated cytokine production in uninfected epi-
thelial cells but inhibited cytokine production in rhinovirus-in-
fected epithelial cells (Sharma et al., 2006). This reveals the
complexity of Echinacea constituents: selected compounds might
exhibit immunostimulatory properties, which could be over-
whelmed by the anti-inﬂammatory activity of some other com-
pounds in the course of LPS or virus infection. As expected,
quercetin (compound 3) signiﬁcantly inhibited LPS-stimulated
NO, PGE2, IL-1b and IL-6 levels at 10 lM, which was consistently
observed among all the experiments.
2.2. Inhibition of NO, PGE2 andinﬂammatory cytokines production by
fractions from E. paradoxa var. paradoxa extracts
Considering the very potent inhibition of LPS-induced NO,
PGE2, IL-1b and IL-6 by the ethanol extract of E. paradoxa var.
paradoxa, the ethanol extract of accession PI 631292 by was then
fractionated semi-preparative HPLC (Table 3) and screened indi-
vidual fractions for anti-inﬂammatory activity. The concentrations
of fractions 1–6 screened for cytotoxicity on RAW264.7 cells were
tested at the highest concentrations obtained from fractionation
(Table 4). Fraction 3 at 101 lg/ml and fraction 6 at 187 lg/ml sig-
niﬁcantly decreased cell viability. No cytotoxicity was detected
with fractions 3 and 6 at 50 lg/ml or for any other fractions at
the highest concentrations tested.
Fractions 3, 4, 5 and 6 at the highest concentrations tested dra-
matically reduced NO and PGE2 production (Fig. 2A). The observed
cytotoxicity of fractions 3 and 6 at the concentrations studied may
have partially contributed to reduction of NO and PGE2.
The activities of fractions 3–6 were compared at non-toxic
doses (Fig. 2B). By comparing the effects on NO and PGE2 produc-
tion caused by these four fractions at 3.2 lg/ml, fractions 4 and 5
had the greatest inhibitory ability on PGE2, and fraction 4 most po-
tently inhibited NO. Fraction 5 inhibited NO and PGE2 levels to a
greater extent than did fractions 3 or 6 when all were tested at
20 lg/ml. The inhibition of PGE2 levels by fractions 3, 5 and 6
and the inhibition of NO levels by fractions 3 and 5 all showed a
dose-dependent pattern.
The effects of fractions 1–6 on LPS-induced inﬂammatory cyto-
kineswere also examined. LPS-stimulated IL-1b and IL-6 levelswere
signiﬁcantly reduced by fractions 3, 4, 5 and 6 at their highest con-
centrations (Table 5). When the tested concentrations of fractions
3, 5 and 6 were normalized to the non-cytotoxic dose of 20 lg/ml,
fraction 5 showed the greatest inhibition of IL-1b and IL-6 induction.
LPS induction of TNF-awas signiﬁcantly alleviated by fractions 4, 5
and 6 at highest doses, but not at 20 lg/ml. When RAW264.7 cells
were treated with fractions 1–6 at the highest concentrations with-
out LPS stimulation, different trends were observed (Table 5). Frac-
tions 3 and 5 reduced baseline TNF-a production by 44% and 36%,
respectively, whereas fraction 6 induced TNF-a levels 2.4 above
those observedwith the DMSO control.When the fractions were di-
luted to 20 lg/ml, only fraction 5 inhibited TNF-a levels (by 24%).
Although fraction 4 at 3.2 lg/ml and fraction 5 at 36 lg/ml
similarly suppressed the production of inﬂammatory mediators,
fraction 5 contributed more to extract activity, since the concentra-
tion of fraction 5 proportional to yield (144 lg/ml)wasmuch higher
than the amount tested (36 lg/ml) and fraction 5 exhibited a dose-
dependent activity.
2.3. Effects of combined fractions 4 and 5 of E. paradoxa var. paradoxa
on NO and PGE2 inhibition
Since the most potent anti-inﬂammatory activities were ob-
served with fractions 4 and 5, these were combined examine their
joint effect onLPS-inducedNOandPGE2production.When fractions
4 and 5 at the highest concentrationswere applied in the RAW264.7
cells with LPS stimulation alone and together, the combined frac-
tions demonstrated synergistic inhibition of NO production, as indi-
cated in Fig. 3A. In parallel studies of LPS-induced PGE2, it was
necessary to dilute fraction 5 to 3.2 lg/ml because fraction 5 alone
reduced LPS induced PGE2 by 96% (±1%). Fraction 4 at 1.6 lg/ml
and fraction 5 at 3.2 lg/ml each resulted in a moderate reduction
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of PGE2, and, when combined, these fractions resulted in greater
inhibition of PGE2 (Fig. 3B).
The effects of combined fractions 4 (1.6 lg/ml) and 5 (3.2 lg/
ml) on LPS induced IL-1b, IL-6 and TNF-a levels at 8 h were also
determined (data not shown). Combined fractions signiﬁcantly
inhibited IL-6 to a greater extent than did the individual fractions,
showing a synergistic effect. However, LPS-stimulated TNF-a level
was not altered by fraction 4 or/and fraction 5 at 8 h. IL-1b was not
elevated in LPS treated macrophages at 8 h.
2.4. GC–MS analysis of active fractions of E. paradoxa var. paradoxa
ethanol extract
GC–MS was employed to identify the constituents in the active
fractions 3–6. As indicated in Fig. 4, Bauer ketones 20 (compound
4) and 21 (compound 5) were identiﬁed in fraction 3. Three classes
of compounds were identiﬁed in fraction 4: (1) polyacetylenes and
polyenes, including alkamide 2 (compound 6), alkamide Chen 1
(compound 7) and Bauer ketone 21 (compound 5); (2) polyunsat-
Compound 1 Bauer ketone 23 
Compound 2 Bauer ketone 24 
Compound 3        Quercetin 
Compound 4 Bauer ketone 20 
Compound 5 Bauer ketone 21 
Compound 6 Alkamide 2 
Compound 7 Alkamide Chen 1 
Compound 8 Linoleic 
acid 
Compound 9 
α-
linolenic 
acid 
Compound 10 Bauer ketone 22 
Compound 11 Bauer ketone 25 
Fig. 1. Compounds 1–11.
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urated fatty acids, including linoleic acid (compound 8) and a-lin-
olenic acid (compound 9); and (3) carbohydrates. Fraction 5 was
rich in Bauer ketones 22 (compound 10), 23 (compound 1) and
24 (compound 2), which comprised 96% of total dry weight Bauer
ketones 23 (compound 1) and 24 (compound 2) were also found in
fraction 6. There were also unidentiﬁed peaks in each fraction.
Alkamide 2 and Chen alkamide 1 (compounds 6, 7) identiﬁed in
fraction 4 have been reported to inhibit PGE2 production signiﬁ-
cantly at 50 lM (LaLone et al., 2007). However, alkamide 2 or Chen
alkamide 1 (compounds 6, 7) could not account for the activity of
fraction 4, since neither of them reached 20 lM in fraction 4 at
3.2 lg/ml. Two essential unsaturated fatty acids, linoleic acid and
Table 1
Provenances and vouchers of Echinacea accessions evaluated.a
Taxon Accession No. Provenance Herbarium voucher
E. angustifolia Ames 24996 Burleigh Co., North Dakota M.P. Widrlechner, 26 June 2009
E. pallida Ames 28968 Synthetic populations from Central Iowa M.P. Widrlechner, 2 July 2009
E. pallida PI 631274 Creek Co., Oklahoma M.P. Widrlechner, 2 July 2009
E. paradoxa Ames 27724 Laclede Co., Missouri J. McCoy, 19 October 2004
E. paradoxa var. paradoxa PI 631292 Stone Co., Arkansas M.P. Widrlechner, 2 July 2009
E. purpurea Ames 27468 Madison Co., Ohio M.P. Widrlechner, 26 June 2009
a All vouchers are deposited at ISC (Ada Hayden Herbarium, Iowa State University, Ames, Iowa).
Table 2
Effects of Echinacea ethanol extracts on production of inﬂammatory mediators in RAW264.7 cells.
Treatmentsa Endpointsb
NO (% of DMSO + LPS
control)c
PGE2 (% of
DMSO + LPS control)c
IL-1b (% of
DMSO + LPS control)c
IL-6 (% of
DMSO + LPS control)c
TNF-a (% of
DMSO + LPS control)c
TNF-a (% of
DMSO)d
E. angustifolia (Ames
24996)
103 ± 5 77 ± 4 90 ± 4 104 ± 3 101 ± 4 195 ± 23
E. pallida (Ames 28968) 69 ± 8 80 ± 1 82 ± 3 83 ± 3 87 ± 4 171 ± 16
E. pallida (PI 631274) 77 ± 2 62 ± 2 72 ± 2 81 ± 2 88 ± 4 143 ± 12
E. paradoxa (Ames 27724) 61 ± 1 87 ± 6 80 ± 8 80 ± 2 89 ± 1 227 ± 44
E. paradoxa var. paradoxa
(PI 631292)
54 ± 5 68 ± 2 47 ± 3 74 ± 5 95 ± 3 199 ± 24
E. purpurea (Ames 27468) 77 ± 4 68 ± 4 87 ± 2 92 ± 3 93 ± 3 352 ± 33
Quercetin (compound 3) 37 ± 3 22 ± 9 26 ± 5 66 ± 5 103 ± 2 72 ± 3
a RAW264.7 cells were treated with six Echinacea ethanol extracts at 20 lg/ml, DMSO control and 10 lM of quercetin, respectively, with or without 1 lg/ml LPS. Quercetin
was included as a positive control, inhibiting LPS-induced NO and PGE2 production signiﬁcantly.
b The levels of inﬂammatory mediators were detected after 8 h (PGE2) or 24 h (NO, IL-1b, IL-6 and TNF-a) treatment.
c The (Media + DMSO + LPS) control group was standardized at 100% of production of NO (10.9 ± 0.7 lM), PGE2 (3.38 ± 0.20 ng/ml), IL-1b (140.5 ± 14.3 pg/ml), IL-6
(23.1 ± 1.0 ng/ml) and TNF-a (30.8 ± 1.2 ng/ml). Data were expressed as% of the (Media + DMSO + LPS) control ± SE (N = 3). Bold and italics mean signiﬁcant difference (bold
p 6 0.05 and italics p 6 0.001) from the (Media + DMSO + LPS) control group.
d The (Media + DMSO) control group was normalized to 100% of TNF-a production (0.18 ± 0.02 ng/ml). Data were expressed as % of the (Media + DMSO) control ± SE (N = 3).
Treatments without LPS revealed no change in the other endpoints compared to (Media + DMSO) controls (data not shown).
Table 3
(A) Solvent gradient for fractionation of E. paradoxa var. paradoxa ethanol extract. (B) Elution time periods for fraction collection.
(A)
Time (min) 0–13 13–14 14–21 21–66 66–69 69–73 73–75 75–80
Solvent Aa (%) 90–80 80–60 60 60–20 20–0 0 0–90 90
Solvent Bb (%) 10–20 20–40 40 40–80 80–100 100 100–10 10
(B)
Fractions 1 2 3 4 5 6
Elution time (min) 5–11 11–29 29–51 51–60 60–67 67–80
Concentration (mg/ml) 184 75 101 3.2 36 187
a Solvent A: 0.1% acetic acid in endotoxin-free water.
b Solvent B: acetonitrile.
Table 4
Cytotoxicity of six fractions from Echinacea paradoxa var. paradoxa.a
Fractions Yield
(mg)
Concentrationb (lg/
ml)
Viability (% of DMSO control ± SE, p-
value)
Diluted concentration (lg/
ml)
Viability (% of DMSO control ± SE, p-
value)
1 920 184 93 ± 7 (0.262) – –
2 93 75 90 ± 3 (0.1338) – –
3 25.2 101 68 ± 3 (<0.0001) 50 108 ± 9 (0.3911)
4 0.8 3.2 89 ± 8 (0.0764) – –
5 36 36 104 ± 3 (0.5964) – –
6 70 187 55 ± 3 (<0.0001) 50 121 ± 3 (0.0046)
a The viability of each fraction was denoted as% of DMSO control ± SE (N = 3). The number in brackets represents the p-value for comparison of fraction treatment groups to
the DMSO control group. Boldface p-value refers to signiﬁcant difference (p < 0.05).
b The tested concentrations of each fraction were the highest concentrations obtained from the fractionation. They were also used in the NO, PGE2 and inﬂammatory
cytokine screening (Fig. 1A and Table 5).
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Fig. 2. Inhibition of NO and PGE2 production by the fractions from a 2009 extract of Echinacea paradoxa var. paradoxa (PI 631292) in LPS stimulated RAW264.7 cells. (A)
Production of NO and PGE2 after treatment with six fractions at their highest concentrations obtained. (B) Production of NO and PGE2 after treatment of fractions 3, 5 and 6 at
three doses up to the highest dose obtained or the dose shown to be non-toxic (Table 3). The data were expressed as % of (Media + DMSO + LPS) control ± SE (N = 3), and the
(Media + DMSO + LPS) control group was set at 100% of NO production (15.5 lM ± 0.4 in (A) and 18.9 ± 1.7 lM in (B)) and PGE2 production (2.8 ± 0.2 ng/ml in (A) and
3.3 ± 0.1 ng/ml in (B)). Asterisks reﬂect signiﬁcant differences (⁄p < 0.05 and ⁄⁄p < 0.001) from the (Media + DMSO + LPS) control group. Treatments without LPS revealed no
change compared to (Media + DMSO) controls (data not shown).
Table 5
Effects of fractions from Echinacea paradoxa var. paradoxa on inﬂammatory cytokine production in RAW264.7 Cells.
Treatments Endpoints
Fractions Concentration
(lg/ml)
IL-1b (% of DMSO + LPS
control)a
IL-6 (% of DMSO + LPS
control)a
TNF-a (% of DMSO + LPS
control)a
TNF-a (% of
DMSO)b
1 184 89 ± 7 88 ± 3 94 ± 1 110 ± 6
2 75 73 ± 7 86 ± 3 99 ± 3 104 ± 2
3 101 31 ± 2 39 ± 4 90 ± 1 56 ± 4
20 59 ± 4 89 ± 1 97 ± 4 98 ± 9
4 3.2 57 ± 3 51 ± 2 85 ± 4 81 ± 7
5 36 11 ± 2 42 ± 1 78 ± 4 64 ± 8
20 21 ± 3 59 ± 3 89 ± 1 76 ± 5
6 187 2 ± 1 50 ± 3 43 ± 6 236 ± 10
20 55 ± 3 74 ± 4 95 ± 4 87 ± 12
Quercetin (Compound 3) 10 lM 10 ± 2 53 ± 1 107 ± 7 81 ± 17
a The levels of IL-1b, IL-6 and TNF-a after treatment with Echinacea paradoxa var. paradoxa fractions at the highest concentrations and 20 lg/ml for fractions 3, 5 and 6 were
compared to those of the (Media + DMSO + LPS) control group in 1 lg/ml LPS induced RAW264.7 cells. Data were expressed as mean ± SE (N = 3). IL-1b production, IL-6
production and TNF-a production of the (Media + DMSO + LPS) control group were 143.6 ± 14.5 pg/ml, 27.1 ± 0.9 ng/ml and 39.8 ± 2.3 ng/ml, respectively. Bold and italics
represent signiﬁcant differences (bold p < 0.05 and italics p < 0.001) from the (Media + DMSO + LPS) control group.
b The levels of TNF-a with the above-mentioned treatment groups were compared to that of the (Media + DMSO) control group (0.41 ± 0.02 ng/ml) in RAW264.7 cells
without LPS addition. Treatments without LPS revealed no change in the other endpoints compared to (Media + DMSO) controls (data not shown).
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a-linolenic acid (ALA) (compounds 8, 9), were also identiﬁed in the
fraction 4. ALA (compound 9), an x-3 PUFA found mainly in plants,
was reported to have anti-inﬂammatory activity in the animal
model (carrageenan-induced paw edema in rats) (Ren et al.,
2007). In the RAW264.7 cell model, ALA (compound 9) was found
to inhibit LPS-induced NO and PGE2 production, and protein and
mRNA expression levels of the iNOS and COX-2 enzymes (Ren
et al., 2007). However, further fractionation of fraction 4 did not
yield any potent subfraction, indicating that constituent interac-
tions might be responsible for the majority of its activity.
2.5. Dose-dependent activity of Bauer ketones identiﬁed in fraction 5
of E. paradoxa var. paradoxa
Due to its promising anti-inﬂammatory activities and relatively
simple chemical proﬁle, the components in fraction 5 were further
quantiﬁed by GC–MS (Table 6). Fraction 5 (3.2 lg/ml) by dry
weight was composed of 3.1 lM Bauer ketone 22 (compound
10), 1.6 lM Bauer ketone 23 (compound 1) and 9.7 lM Bauer ke-
tone 24 (compound 2).
To investigate the bioactivity of Bauer ketones, three doses of
Bauer ketones 22, 23 and 24 (compounds 10, 1, 2) were applied
in RAW264.7 cells with or without LPS induction, as described in
Section 4. As indicated in Fig. 5A, all three doses of Bauer ketone
24 (compound 2) signiﬁcantly decreased LPS-induced NO produc-
tion with a dose-dependent relationship. Bauer ketone 23 (com-
pound 1) signiﬁcantly inhibited NO induction at 10 and 5 lM,
and Bauer ketone 22 (compound 10) resulted in a moderate de-
crease of NO level at 10 lM. Dose-dependent inhibition of LPS-
induced PGE2 production was observed with Bauer ketones 22,
23 and 24 (compounds 10, 1, 2) (Fig. 5A). All three doses of Bauer
ketone 23 (compound 1) signiﬁcantly reduced PGE2 levels, but
Bauer ketones 22 and 24 (compounds 10, 2) did not affect PGE2
levels signiﬁcantly at 1.6 lM.
2.6. Contribution of Bauer ketones in fraction 5 of E. paradoxa var.
paradoxa to inhibition of NO, PGE2 and inﬂammatory cytokine
production
To determine the degree to which Bauer ketones 22, 23 and 24
(compounds 10, 1, 2) at concentrations found in fraction 5 contrib-
Fig. 3. Synergistic inhibition of NO (A) and additive inhibition of PGE2 (B) production by fractions 4 and 5 from Echinacea paradoxa var. paradoxa in LPS-stimulated RAW264.7
cells. RAW264.7 cells were treated with combined or individual fraction 4 and fraction 5 at indicated concentrations, with 1 lg/ml LPS. Data were expressed as% of the
(Media + DMSO + LPS) control ± SE (N = 3), and the (Media + DMSO + LPS) control group was set at 100% of NO production (14.8 ± 0.7 lM) and PGE2 (2.2 ± 0.4 ng/ml)
production. Asterisks reﬂect signiﬁcant differences (⁄⁄p < 0.001) from the (Media + DMSO + LPS) treatment group. Treatments without LPS revealed no change compared to
(Media + DMSO) controls (data not shown).
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uted to the anti-inﬂammatory activity observed when that fraction
was tested at 3.2 lg/ml, the effects of individual or combined syn-
thesized Bauer ketones on LPS-stimulated NO, PGE2 and pro-
inﬂammatory cytokine production was examined. As shown in
Fig. 5B, when compared to (Media + DMSO + LPS) control, all treat-
ments with Bauer ketone 24 (compound 2), including Bauer ke-
tones 22 + 23 + 24 (compounds 10 + 1 + 2), Bauer ketones 22 + 24
(compounds 10 + 2), Bauer ketones 23 + 24 (compounds 1 + 2),
and Bauer ketone 24 (compound 2) alone, decreased LPS-induced
NO production signiﬁcantly. Bauer ketone 22 (compound 10) did
not exert any effect on NO levels. Multiple comparison with Tukey
adjustment was employed to compare among the effects we ob-
served from combined and individual Bauer ketones and from
fraction 5 at 3.2 lg/ml. Despite the lack of an effect by Bauer ketone
23 (compound 1) alone, Bauer ketones 23 + 24 (compounds 1 + 2)
did inhibit NO production to a greater extent than did Bauer ketone
24 (compound 2) alone, which suggested that the interaction of
Bauer ketones 23 and 24 (compounds 1, 2) could result in stronger
inhibition of LPS-inducedNO production. A similar relationshipwas
found between Bauer ketones 22 + 23 + 24 (compounds 10 + 1 + 2)
and Bauer ketones 22 + 24 (compounds 10 + 2). Although Bauer
ketones have inhibitory properties at concentrations present in
fraction 5 at 3.2 lg/ml, fraction 5 itself did not exhibit any effect
on NO induction at 3.2 lg/ml. This suggests thatminor constituents
might counteract Bauer ketones, thus weakening the anti-inﬂam-
matory potential of fraction 5. Moreover, fraction 5 at 20 lg/ml
and Bauer ketones 23 + 24 (compounds 1 + 2) reduced LPS-stimu-
lated NO production to the same extent.
LPS-stimulated PGE2productionwas dramatically reduced by all
treatments with Bauer ketones (p < 0.001), except for the treatment
with Bauer ketone 22 (compound 10) alone. Multiple comparison
demonstrated that reduction of PGE2 by Bauer ketones 23 + 24
(compounds 1 + 2) was signiﬁcantly greater than that by individual
Bauer ketones 23 (compound 1) or 24 (compound 2). Addition of
Bauer ketone 22 (compound 10) did not affect the degree of inhibi-
tion caused by Bauer ketones 23 or/and 24 (compounds 1, 2). No sig-
niﬁcant differencewas foundbetween reduction of PGE2 by fraction
5 and that by Bauer ketones 23 and/or 24 (compounds 1, 2). This
indicated that Bauer ketones 23 and 24 (compounds 1, 2) contrib-
uted to PGE2 inhibition by fraction 5 at 3.2 lg/ml.
Synthesized Bauer ketones also exerted inhibitory effects on
LPS-induced IL-1b and IL-6 production. As shown in Fig. 6A, all
the treatments containing Bauer ketone 24 (compound 2) dramat-
ically inhibited IL-1b induction compared to (Media + DMSO + LPS)
control. Fig. 6B illustrates a moderate decrease of IL-6 induction by
all treatments containing Bauer ketone 24 (compound 2) compared
to (Media + DMSO + LPS) control. LPS-induced TNF-a production
level was not changed by any treatments with Bauer ketones or
fraction 5 (Fig. 6C). No cytotoxicity was found with Bauer ketones
at the screened concentrations.
In summary, our results indicate that a combination of Bauer
ketones 23 and 24 (compounds 1, 2) had the greatest potential
to inhibit NO and PGE2 production, and Bauer ketone 24 (com-
pound 2) accounted for the inhibition of IL-1b and IL-6 by fraction
5. Bauer ketone 22 (compound 10) at 3.1 lM did not exert any
effects on production of the tested endpoints. Some other minor
constituents might have antagonistic effects which comprised the
activity of Bauer ketones 23 and 24 (compounds 1, 2) as demon-
strated by NO and IL-1b screening. Results of testing three doses
of Bauer ketones suggested that Bauer ketone 24 (compound 2)
was more effective in suppressing NO production and Bauer ketone
23 (compound 1) was more effective for PGE2 inhibition. Although
three Bauer ketones all exhibited anti-inﬂammatory potential to
different extent, only Bauer ketones 23 and 24 (compounds 1, 2)
contributed to the activity of fraction 5 considering their concen-
trations in the fraction 5 at 3.2 lg/ml. Combination of Bauer ke-
tones at different ratios might lead to different level of inhibition.
Binns et al. (2002a) indicated that Bauer ketones were impor-
tant chemotaxonomic markers based on the lipophilic phytochem-
ical proﬁles of various Echinacea species. E. paradoxa and E. pallida
exhibited similar pattern of ketoalkenynes, including Bauer ke-
tones 22, 23, 24 and 25 (compounds 10, 1, 2, 11), but contained
alkamides at low concentrations (Bauer and Foster, 1991; Bauer
et al., 1988). In contrast, the roots of E. purpurea and E. angustifolia
Fig. 4. GC–MS analysis of bioactive fractions from E. paradoxa var. paradoxa. Total ion chromatograms of fractions 3, 4, 5 and 6 are displayed. Peaks were identiﬁed by
comparing their retention time and mass spectra to authentic standards.
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were mainly characterized by the presence of alkamides (Bauer
and Remiger, 1989).
Limited research has been conducted on the bioactivity of Bauer
ketones. Our work demonstrates that E. paradoxa var. paradoxa,
which is also rich in Bauer ketones, could partly attribute its
anti-inﬂammatory activity (inhibitory ability on NO, PGE2, IL-1b
and IL-6 production) to Bauer ketones 23 and 24 (compounds 1,
2). Prior results from our laboratory (LaLone et al., 2009, 2010) re-
ported the inhibition of PGE2 and NO production by these ketones
at concentrations found in E. pallida and E. angustifolia, and the re-
sults in the present report with concentrations of Bauer ketones 23
and 24 (compounds 1, 2) that were found in E. paradoxa var. parad-
oxa were in agreement with the earlier results. Apart from its anti-
inﬂammatory activity, Bauer ketone 24 (compound 2) from
E. pallida has also been reported to inhibit the growth of human
cancer cell lines possibly by arresting the cell cycle in the G1 phase
and promoting apoptotic cell death (Chicca et al., 2010). Bauer
ketone 24 (compound 2) is evidently permeable above
10  106 cm s1 across the Caco-2 monolayer, suggesting poten-
tial oral bioavailability (Chicca et al., 2008). Therefore, Bauer ke-
tone 24 (compound 2) might be a promising candidate as an
anti-inﬂammatory and anti-tumor agent. However, further investi-
gation is necessary to conﬁrm this in appropriate animal models.
2.7. Effects of Bauer ketones on the expression levels of COX-2 and
iNOS
COX and iNOS are the critical enzymes catalyzing the committed
step in the production of PGE2 (Bakhle and Botting, 1996) and NO
(MacMicking et al., 1997), respectively. COX-1 is constitutively ex-
pressed in various cells and tissues, but COX-2 is an inducible form
in response to LPS or cytokines (Bakhle and Botting, 1996). To
examinewhether Bauer ketones 23 and 24 (compounds 1, 2) inhibit
PGE2 and NO levels through regulation of COX-2 and iNOS protein
expression, RAW264.7 cells were treated with Bauer ketones at the
concentrations present in 3.2 lg/ml of fraction 5 to measure levels
of COX-2 and iNOS by usingWestern blot, as described in Section 4.
As shown in Fig. 7 1 lg/ml LPS induced the expression of COX-2
and iNOS, and COX-1 to a lesser extent. All the treatments did not
alter the expression levels of COX-1 induced by LPS. Bauer ketone
24 (compound 2) increased the expression of COX-2 signiﬁcantly
compared to DMSO control in LPS-induced macrophages, whereas
only a trend towards increased COX-2 was observed with Bauer ke-
tone 23 (compound 1). The combined Bauer ketones were more
effective than were individual Bauer ketones, with a 2-fold in-
crease in COX-2 levels in relation to (Media + DMSO + LPS) control.
LaLone et al. (2010) reported that Bauer ketone 23 (compound 1)
identiﬁed in an E. angustifolia extract had the capacity to increase
COX-2 expression signiﬁcantly at 5 lM in LPS-stimulated macro-
phages. In contrast, Bauer ketone 23 (compound 1) inhibited LPS-
induced COX-2 activity at 0.83 lM (LaLone et al., 2010). Therefore,
it is speculated that Bauer ketones 23 and 24 (compounds 1, 2)
might reduce activity of COX-2 enzyme rather than decrease
COX-2 expression at translational levels, and consequently inhibit
PGE2 production in LPS-stimulated macrophages. However, the
mechanism underlying an increase in the amount of COX-2 protein
is unclear.
Although inhibition of iNOS expression has been found with
alkamides (Hou et al., 2010), neither Bauer ketones nor fraction 5
from E. paradoxa affected LPS-induced iNOS expression. This indi-
cates that the inhibition of NO production by Bauer ketones
23 + 24 (compounds 1 + 2) cannot be attributed to iNOS regulation
at the protein level. a-Tubulin, as a loading control, was constitu-
tively expressed among all treatments (data not shown).
3. Conclusions
Echinacea species, especially the extensively studied E. purpurea,
have been found to inhibit inﬂammatory mediators in different cell
model systems (Canlas et al., 2010; Sharma et al., 2010). Our
experiments demonstrate that (1) E. paradoxa var. paradoxa (PI
631292) has more potent anti-inﬂammatory activity as measured
by inﬂammatory mediators including NO, PGE2, IL-1b and IL-6 in
RAW264.7 cells than do the three most common medicinal species
of Echinacea (Table 4); (2) Bauer ketones from E. paradoxa var.
paradoxa played an important role in the inhibition of inﬂamma-
tory mediator production in LPS-stimulated RAW264.7 cells. Bauer
ketones 23 and 24 (compounds 1, 2) were identiﬁed as key constit-
uents contributing to NO and PGE2 inhibition by E. paradoxa var.
paradoxa. Moreover, Bauer ketone 24 (compound 2) at the concen-
tration found in fraction 5 was capable of signiﬁcantly inhibiting
IL-1b and IL-6 secretion.
The potent anti-inﬂammatory activity found in E. paradoxa var.
paradoxa suggests that it may be promising for medicinal use. If so,
Table 6
Quantitation of Bauer ketones in fraction 5.a
Nomenclature Structure Concentration
(lM in 3.2 lg/ml of F5)
Tetradeca-8Z-ene-11,13-diyn-2-one
(Bauer ketone 22, compound 10)
3.1
Pentadeca-8Z-ene-11,13-diyn-2-one
(Bauer ketone 23, compound 1)
1.6
Pentadeca-8Z,13Z-dien-11-yn-2-one
(Bauer ketone 24, compound 2)
9.7
a Compounds were identiﬁed according to retention times and mass spectra from GC–MS. Synthesized Bauer ketones 22–24 were used as internal standards to quantify
compounds in fraction 5.
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its cultivation should be encouraged, as its native populations are
limited and could be threatened by wild harvesting (Kindscher,
2006). Furthermore, identiﬁcation of the key contributors, Bauer
ketones 23 and 24 (compounds 1, 2), from E. paradoxa var. parad-
oxa by bioactivity-guided fractionation suggests their potential as
anti-inﬂammatory agents per se. It is hoped that these ﬁndings
on the identiﬁcation of active constituents in Echinacea species
may help guide the development of Echinacea preparations with
improved efﬁcacy as botanical dietary supplements.
4. Experimental
4.1. General experimental procedures
A semi-preparative HPLC system was used for fractionation,
which consisted of a model 508 autosampler, a YMC-pack ODS-
AM 250  10 mm C18 column (YMC, Kyoto, Japan), a Beckman-
Coulter System Gold with a 126 solvent module and a model 168
detector (Beckman Coulter, Fullerton, CA). GC–MS analysis was
performed by using an Agilent Technologies gas chromatograph
(6890 series), equipped with a capillary column (HP-5MS fused sil-
ica column coated with 5% diphenyl 95% dimethyl polysiloxane,
30 m, 250 lm bore, 0.25 lm ﬁlm thickness) and a model 5973
mass spectrometer as detector (all from Agilent Technologies, Palo
Alto, CA). DMEM, fetal bovine serum, sodium bicarbonate and pen-
icillin/streptomycin were purchased from Invitrogen (Carlsbad,
CA). DMSO, quercetin (compound 3) and ursolic acid were pur-
chased from Sigma–Aldrich (St. Louis, MO). CellTiter 96 AQueous
One solution Reagent and Griess reaction kit were from Promega
(Madison, WI). Biotrek PGE2 enzyme immunoassay system (GE
Healthcare, Piscataway, NJ) and BD OptEIATM ELISA sets (BD Bio-
sciences, San Diego, CA) were used for bioactivity assays. BCA Pro-
tein Assay Reagent was purchased from Pierce (Rockford, IL) and
antibodies used in the Western blot were from Santa Cruz Biotech-
nology (Santa Cruz, CA).
4.2. Plant materials
Plant materials were obtained from the U.S. Department of
Agriculture North Central Regional Plant Introduction Station
(NCRPIS), Ames, IA. Accessions of Echinacea samples used in this
study (Table 1) included: E. angustifolia (Ames 24996), E. pallida
(Ames 28968), E. pallida (PI 631274), E. paradoxa (Ames 27724),
E. paradoxa var. paradoxa (PI 631292) and E. purpurea (Ames
Fig. 5. Inhibition of NO and PGE2 production by combined or individual synthetic Bauer ketones in LPS-stimulated RAW264.7 cells. (A) Dose-dependent inhibition of NO and
PGE2 production by synthetic Bauer ketones 22, 23 and 24 (compounds 10, 1, 2). (B) NO and PGE2 levels after treatment with combined or individual synthetic Bauer ketones
at the concentrations present in fraction 5 (Table 6). The highest and lowest doses were set at the concentrations of ketone 24 (compound 2, 9.7 lM, rounded to 10 lM) and
23 (compound 1, 1.6 lM) present in 3.2 lg/ml of fraction 5. Data were expressed as % of the (Media + DMSO + LPS) control ± SE (N = 3), and the (Media + DMSO + LPS) control
group was normalized at 100% of NO production (11.4 ± 0.8 lM in (A), 23.2 ± 4.6 lM in (B)) and PGE2 production (2.6 ± 0.2 ng/ml in (A), 2.2 ± 0.3 ng/ml in (B)). Asterisks
reﬂect signiﬁcant differences (⁄p < 0.05 and ⁄⁄p < 0.001) from the (Media + DMSO + LPS) treatment group. Values labeled with different letters demonstrate a signiﬁcant
difference (p < 0.05) between them. Values with both a and b have signiﬁcant difference from values with c only. Treatments without LPS revealed no change compared to
(Media + DMSO) controls (data not shown).
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27468). More detailed information about the original sources and
availability of these accessions can be found in the Germplasm Re-
sources Information Network (GRIN) database at http://www.ars-
grin.gov/npgs/acc/acc_queries.html. Roots of these plants, har-
vested at the NCRPIS in November 2009, were dried for 8 days at
40 C with constant humidity in a forced-air dryer. The dried mate-
rials were ground with a 40-mesh screen in a Wiley mill and then
stored at 20 C under N2 prior to extraction.
4.3. Extraction
For each Echinacea accession, dried root powder (1 g) was
extracted with EtOH–H2O (95:5, v/v) for 6 h by using a Soxhlet
extractor. After extraction, the ethanol solvent was removed with
a rotary evaporator at 35 C, followed by lyophilization, yielding
the dried samples. The percentage yield of each accession (% of
dried root powder) was as follows: Ames 24996 30.5%, Ames
Fig. 6. Effects of combined or individual Bauer ketones at the concentrations present in fraction 5 (Table 6) on inﬂammatory cytokine production in LPS-stimulated
RAW264.7 cells. The levels of IL-1b (A), IL-6 (B) and TNF-a (C) after treatment with combined or individual Bauer ketones were compared to those of the
(Media + DMSO + LPS) control group in 1 lg/ml LPS induced RAW264.7 cells. Data were expressed as mean ± SE (N = 3). Asterisks reﬂect signiﬁcant differences (⁄p < 0.05 and
⁄⁄p < 0.001) from the (Media + DMSO + LPS) control group. Values labeled with different letters demonstrate a signiﬁcant difference (p < 0.05) between them. Values with two
letters, i.e. cd, are not signiﬁcantly different from values with either of these letters. Treatments without LPS revealed no change compared to (Media + DMSO) controls (data
not shown).
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28968 22.9%, PI 631274 16.9%, Ames 27724 20.5%, PI 631292 19.2%
and Ames 27468 11.5%. The dried samples were redissolved in
the minimal volume of DMSO that ensured complete sample
solubilization. The concentrations of the ethanol extracts
obtained from each of these accessions were 116, 78, 48, 66, 59
and 21 mg/ml, respectively. None of these extracts showed
cytotoxicity in the cell viability assay (described as below), which
was consistent with previous work by LaLone et al. (2007). The
ethanol extracts of Echinacea species were stored at 20 C under
argon. All extracts were assayed for endotoxin, and levels were
undetectable by Lymulus Amebocyte Lysate assay, whose detect-
able level was above 0.0001 EU/ml (Bio Whittaker, Walkersville,
MD).
4.4. Semi-preparative HPLC fractionation
Dried ethanol extract (2 g) of E. paradoxa var. paradoxa (PI
631292) was dissolved in EtOH–H2O (42:58, v/v) and then ﬁltered
through a 0.45 lm ﬁlter. The ﬁltrate was fractionated by using the
semi-preparative HPLC system described in Section 4.1. Fraction-
ation was conducted by using a mobile phase of 0.1% AcOH in
endotoxin-free H2O (solvent A) and CH3CN (solvent B). The gradi-
ent of solvents A and B throughout the fractionation and the
elution time periods for collecting each fraction are shown in
Table 2. Fractions dissolved in DMSO were stored at 80 C under
Ar to avoid degradation of potentially unstable Bauer ketones. In
total, 6 fractions were obtained from the E. paradoxa var. paradoxa
ethanol extract, with yields and original concentrations (mg/ml)
shown in Table 3.
4.5. GC–MS analysis
The carrier gas for GC–MS analysis was He, at a ﬂow rate of
1.2 ml/min. Oven temperature was initially 80 C for 2 min, then
was increased to 200 C at a rate of 10 C/min and held at 200 C
for 5 min. Injector and detector temperatures were set at 250 C.
The fractions in DMSO were dried with nitrogen gas and then
redissolved in CH3CN. One microliter of Echinacea fraction or syn-
thesized standards was injected automatically in splitless mode.
Compounds in each fraction were identiﬁed by comparing their
retention times and mass spectral data with those in the NIST Mass
Spectral Library (NIST 08). Pentadeca-8Z-ene-11, 13-diyn-2-one
(Bauer ketone 23, compound 1) and pentadeca-8Z, 13Z-dien-11-
yn-2-one (Bauer ketone 24, compound 2) were quantiﬁed in our
fractions on the basis of synthesized Bauer ketones as internal
standards. The amount of added standard was adjusted for the
small amount of impurities present in the standard preparations.
Tetradeca-8Z-ene-11, 13-diyn-2-one (Bauer ketone 22, compound
10) was quantiﬁed in relation to Bauer ketones 23 and 24. The
standard error for the measurement of all Bauer ketones was
3.22%, based on three measurements of synthesized Bauer ketones.
4.6. Bauer ketone synthesis
Bauer ketones were chemically synthesized following the pro-
cedure developed by Kraus et al. (2007) and described in detail
in the Ph.D. thesis of Jaehoon Bae (Bae, 2006). Based on 1H- and
13C-NMR spectra (Kraus et al., 2007), the percent purity for syn-
thetic Bauer ketones 22, 23 and 24 (compounds 10, 1, 2) was
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Fig. 7. Effects of combined or individual Bauer ketones on LPS-induced COX-2, COX-1 and iNOS protein levels in RAW264.7 cells. Treatments of controls, Bauer ketones or
fraction 5 were applied to RAW264.7 cells with LPS induction. (Media + DMSO) without LPS addition was used as a negative control. (A) One replicate of protein (COX-2, COX-
1 or iNOS) bands identiﬁed by Western blot. Bands were quantiﬁed with a densitometer, and results were shown in (B) as percentage of the (Media + DMSO + LPS)
control ± SE (N = 3 or 4). Asterisks reﬂect signiﬁcant differences (⁄p < 0.05 and ⁄⁄p < 0.001) from the (Media + DMSO + LPS) control group. a-Tubulin, as a loading control, was
constitutively expressed among all treatments (data not shown).
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80%, 90% and 99%, respectively. All synthetic Bauer ketones were
stored at 80 C under Ar to avoid degradation.
4.7. Cell culture and treatments
RAW264.7 mouse macrophage cells were purchased from the
American Type Culture Collection (ATCC, Manassas, VA) and cul-
tured as previously described (Hammer et al., 2007) except for
an adjustment to our incubator to hold cells at 95% relative humid-
ity. The medium for culturing RAW264.7 cells was high glucose
DMEM supplemented with 10% FBS, 2% sodium bicarbonate and
1% penicillin/streptomycin.
Prior to treatment, 0.64  105 cells/well (for NO and cytokine)
or 1  105 cells/well (for PGE2) were plated in 24-well tissue-
culture plates with 0.5 ml culture medium/well and incubated
for 24 h. DMSO vehicle control, a quercetin (compound 3) positive
control, and Echinacea extracts, fractions or synthesized com-
pounds were diluted into cell media for a ﬁnal DMSO concentra-
tion of 0.1% v/v, well below the toxic level of DMSO. Diluted
samples were applied to cells with/without 1 lg/ml LPS simulta-
neously. Following treatment for 8 h (for PGE2) or 24 h (for NO
and cytokines), supernatants were collected for storage at 80 C
(for PGE2 and cytokines) or for immediate NO measurement. For
cell viability assays, 1  104 cells/well were plated in 48-well tis-
sue-culture plates with 0.2 ml culture medium/well and incubated
for 24 h. Diluted samples including (Media + DMSO) control, Echin-
acea extracts, fractions, synthesized compounds and ursolic acid
controls in cell media were applied to cells without LPS stimulation
for 24 h. For all experiments, three individual plates from three
corresponding ﬂasks of cells were included as three replicates.
4.8. Cell viability assay
Following 24 h treatment, supernatants were replaced by
200 ll fresh media and 30 ll of CellTiter 96 AQueous One solution
Reagent for each well. After incubation for 195 min, 200 ll of
supernatant containing dye product was transferred from each
well to 96-well plates, followed by reading absorbance at
562 nm. There were three repeated treatments within each plate.
Viability compared to (Media + DMSO) control was denoted as
the mean absorbance of Echinacea extracts, fractions or synthe-
sized compound divided by the mean absorbance of (Media + DM-
SO) control, expressed as a percentage.
4.9. NO, PGE2 and cytokine measurement
After the supernatants were collected, Griess reaction was used
to determine NO levels according to procedures as described
(Huang et al., 2009). For PGE2 measurement, samples stored at
80 C were thawed at room temperature and then diluted 15-fold
into ddH2O. Biotrek PGE2 enzyme immunoassay system was em-
ployed to measure PGE2 concentrations in cell supernatants based
on manufacturer’s protocols. The levels of TNF-a, IL-1b and IL-6 in
the supernatant samples were analyzed with BD OptEIA™ ELISA
sets according to manufacturer’s instructions. Before the proce-
dures were performed, the samples were diluted 20- to 40-fold
into assay diluent for TNF-a and IL-6 to ensure that sample concen-
trations were within the linear range of a standard curve. Concen-
trations of NO, PGE2 and each type of cytokine produced by our
samples were interpolated from their corresponding standard
curves.
4.10. Western blot analysis
RAW264.7 cells at 80% conﬂuency in 10 cm Petri dishes were
treated with DMSO, Echinacea extracts and 100 lM quercetin
(compound 3) plus 1 lg/ml LPS and DMSO alone for 8 h (for
COX2 and COX1) or for 24 h (for iNOS). Preparation of whole-cell
protein extracts from treated cells was performed as described
by LaLone et al. (2010). The protein concentration was measured
by using the BCA Protein Assay Reagent. An equal amount of total
protein for all treatments was loaded to detect iNOS, COX2, COX1
and a-Tubulin. The iNOS (sc-7271), COX-1 (sc-19998), COX-2 (sc-
19999) and a-Tubulin (sc-8035) mouse monoclonal antibodies
were diluted 1:600, 1:800, 1:500 and 1:1000, respectively, in 7%
milk Tris-buffered saline containing 0.1% Tween 20. The secondary
antibody, horseradish peroxidase-conjugated goat anti-mouse IgG
(sc-2005), was diluted 1:1000 in the above-mentioned solution.
The immunoblot was carried out as described (Przybyszewski
et al., 2001). The signals were detected by ECL and quantiﬁed by
Quantity One Software as described by Hammer et al. (2007).
4.11. Statistical analysis
A randomized complete block design was applied to all experi-
ments. For each experiment, there were three plates of cells receiv-
ing the same treatments. The Media + DMSO ± LPS treatment
within each plate was normalized to 100% and three plates were
considered as ﬁxed blocks. Because of the normalization the control
values appear in the results without standard error (SE). For the
cytotoxicity assay, there were three repeated measurements in
each plate, which were averaged. For PGE2 assays and ELISA, con-
centrations of PGE2 and cytokines for all treatments were log trans-
formed. Results were presented as% of Media + DMSO ± LPS ± SE.
ANOVA analysis using GLM procedures in SAS 9.0 (SAS Institute
Inc., Cary, NC) was conducted to test statistical differences as com-
pared to the Media + DMSO ± LPS controls. For combined Bauer ke-
tone treatments, multiple comparison with Tukey adjustment was
conducted to test statistical differences among them.
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